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STUDY QUESTION: Would letrozole as a primary ovulation induction agent generate better pregnancy rates than clomiphene citrate
(CC) in subfertile women with anovulatory polycystic ovarian syndrome (PCOS)?
SUMMARY ANSWER: Participants receiving letrozole as a primary treatment achieved a signiﬁcantly (P = 0.022) higher clinical pregnancy
rate per patient (61.2%) compared to CC (43.0%).
WHAT IS KNOWN ALREADY: According to a recent Cochrane systematic review (2014), letrozole appears to improve live-birth (LB)
and pregnancy rates in anovulatory women with PCOS, compared to CC. However, the review concluded that the quality of evidence was
low due to poor reporting of study methods and possible publication bias.
STUDY DESIGN, SIZE, DURATION: This double-blind randomized controlled trial (RCT) included 159 participants between April
2007 and June 2014. Subjects were randomly allocated to either CC (n = 79) or letrozole (n = 80) in a 1:1 ratio. Both drugs were encapsu-
lated to look identical. Randomization was performed in mixed blocks and stratiﬁed by patients’ BMI (<30 and 30–35 kg/m2).
PARTICIPANTS/MATERIALS, SETTING, METHODS: The trial included subfertile women diagnosed with PCOS. Treatment started
with one tablet (CC 50 mg, letrozole 2.5 mg) increasing to two in non-responders and continuing until pregnancy or for up to six ovulatory
cycles. Non-responders were crossed over to the other treatment after a 6-week break. Cycles were initially monitored with ultrasound fol-
licle tracking then mid-luteal serum progesterone measurement in subsequent cycles.
MAIN RESULTS AND THE ROLE OF CHANCE: Amongst the 159 participants included in the intention-to-treat analysis, four women
conceived before treatment and six were lost-to-follow-up. The remaining 149 participants (74 on CC and 75 on letrozole) completed
at least the ﬁrst treatment. Women receiving letrozole achieved a signiﬁcantly (P = 0.022; absolute difference [95% conﬁdence interval]
18% [3–33%]) higher pregnancy rate (61.%) than those on CC (43%). The median number of treatment cycles received until pregnancy was
signiﬁcantly (log rank P = 0.038) smaller with letrozole (4[3–5] cycles) compared to CC (6[4–7] cycles). LB rates were not statistically (P = 0.089)
different between the two groups, although there was a trend towards higher rates on letrozole (48.8%) compared to CC (35.4%). After the
crossover, pregnancy and LB rates on letrozole (n = 45; 28.9 and 24.4%, respectively) were not statistically (P = 0.539 and P = 0.601) different
from CC (n = 31; 22.6 and 19.4%).
LIMITATIONS, REASONS FOR CAUTION: One possible limitation of this trial may be the exclusion of PCOS women with BMI >
35 kg/m2, which would limit the applicability of the results in this subgroup of PCOS. However, this group of women are generally excluded
from treatment in the majority of fertility centres, especially in Europe, due to the associated challenges and risks.
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WIDER IMPLICATIONS OF THE FINDINGS: The results of this trial are consistent with the recent Cochrane systematic review.
However, with its robust design, the current RCT provides more valid and compelling evidence for the superiority of letrozole over CC as a
primary ovulation induction agent in PCOS women with 40% increase in pregnancy rates and with a shorter time-to-pregnancy. Furthermore,
the participants in this RCT are a good representation of subfertile PCOS population receiving fertility treatment in Europe and worldwide.
The results are therefore globally generalizable for clinical practice.
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Introduction
Polycystic ovarian syndrome (PCOS) is a very common ovarian endo-
crinopathy affecting 6–8% of women and is the commonest cause of
anovulatory infertility accounting for >80% of all cases (Asuncion et al.,
2000). For decades, clomiphene citrate (CC) has been the standard
ﬁrst line ovulation induction (OI) agent in PCOS women with ovulation
rates of ~85% and pregnancy rates of 35–40% (Dickey and Holtkamp,
1996; Kousta et al., 1997; Imani et al., 2002). This discrepancy
between ovulation and conception rates has been attributed to the
peripheral anti-oestrogenic actions of CC on endometrial develop-
ment and cervical mucus (Massai et al., 1993; Nakamura et al., 1997).
Letrozole, a speciﬁc aromatase inhibitor that reduces oestrogen syn-
thesis, has recently been considered as a potentially better alternative
to CC. In contrast to CC, letrozole is not associated with any anti-
oestrogenic effects on endometrium. This is supported by recent studies
reporting adequate endometrial thickness during letrozole treatment
(Mitwally and Casper, 2001; Al-Omari et al., 2004; Atay et al., 2006).
Furthermore, unlike CC that accumulates in the body because of its long
half-life (2 weeks), letrozole is rapidly eliminated due to its short half-life
(45 h), leading to late follicular rise in circulating oestrogen thereby
enhancing endometrial development with subsequent increase in the
chances of pregnancy (Lipton et al., 1995; Siouﬁ et al., 1997; Young et al.,
1999). The rising oestrogen levels may also result in a shorter FSH win-
dow (mimicking the physiological cycle) with subsequent mono-ovulation
and a lower risk of multiple pregnancy.
Franik et al. (2014) published a Cochrane systematic review of clin-
ical trials comparing aromatase inhibitors versus CC. They concluded
that the quality of evidence in the reviewed trials was low due to poor
reporting of study methods and possible publication bias. One of the
trials in that review, which had a good design, included a high propor-
tion of markedly obese women (BMI >40 kg/m2), which does not
reﬂect clinical practice in the majority of fertility centres worldwide
(Legro et al., 2014). These results are therefore neither conclusive nor
generalizable. The Cochrane review authors stated that further
research is needed to compare letrozole with CC as a primary OI
agent in PCOS women. Furthermore, none of the reviewed trials was
conducted in Europe. Geographical, ethnic, genetic and phenotypical
differences in PCOS as well as differences in clinical practices in differ-
ent parts of the world may limit the generalizability of the review ﬁnd-
ings in Europe. Therefore, the effectiveness of letrozole versus CC
remains uncertain.
The primary objective of this study was to test the hypothesis that
letrozole as a primary OI agent will generate higher pregnancy rates than
CC in anovulatory women with PCOS. The purpose of the crossover
design, was to test the efﬁcacy of each drug as a secondary OI agent.
Materials andMethods
Trial design
This was a single centre, two-arm double-blind RCT. Women not conceiv-
ing with the ﬁrst drug were offered to crossover to the other one.
The trial was approved by West Midlands Research Ethics Committee
(Reference: 07/MRE07/5) and by the Medicines and Healthcare Products
Regulatory Agency (MHRA). It was sponsored by the University of
Nottingham. All participants gave a written informed consent and the trial
was monitored by the Sponsor.
Participants
This study was conducted at the Fertility Unit, Derby Teaching Hospitals NHS
Foundation Trust between April 2007 and June 2014. Eligible participants
were women aged 18–39 years with BMI ≤35 kg/m2, anovulatory infertility,
and a diagnosis of PCOS based on Rotterdam consensus (two of three cri-
teria: oligo-/anovulation, hyperandrogenaemia and sonographic appearance
of polycystic ovaries) (Rotterdam ESHRE/ASRM-sponsored PCOS consensus
workshop group, 2004). Diagnosis of oligo-/anovulation was based on a men-
strual pattern of oligo-/amenorrhoea (cycle >35 days) and/or a low mid-luteal
serum progesterone concentration. Hyperandrogenaemia was diagnosed
either clinically (acne/hirsutism) or biochemically (testosterone ≥2.5 nmol/l or
free androgen index [FAI] ≥5). Ultrasound criteria included ≥12 follicles
(2–9 mm) and/or an ovarian volume of >10 ml (Jonard et al., 2003). All
participants had proven patency of at least one fallopian tube and normal
semen analysis of their male partners (WHO, 1999). We excluded patients
who have received OI within 6 months and those with uncontrolled thyroid
disease or hyperprolactinaemia. Patients with marked hyperandrogenaemia
were screened for adult onset congenital adrenal hyperplasia (by measuring
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serum 17-α-hydroxyl-progesterone concentration) and Cushing syndrome
(by measuring urinary free cortisol).
Interventions
Letrozole and CC were prescribed (by the senior investigator, SA) orally
daily for 5 days starting on Days 2–4 of a menstrual period or a
progestogen-induced bleed (medroxy-progesterone acetate 10mg twice
daily for 5 days). The starting dose was one tablet/day (letrozole 2.5 mg or
CC 50mg) and if ovulation was not achieved, the dose would be doubled in
the second cycle. Ovulation was initially monitored by ultrasound follicle
tracking (performed by an independent qualiﬁed sonographer) and mid-
luteal (cycle Day 21 ± 2) serum progesterone measurement. Ovulation was
diagnosed with a progesterone level of ≥25 nmol/l, a follicle diameter
≥17mm and/or occurrence of pregnancy (positive urinary hCG and ultra-
sound detection of gestational sac). Once ovulation was achieved, further
cycles would be monitored mainly by serum progesterone levels with follicle
tracking as an option. In case of no ovulation and if the participant remained
amenorrheic for ≥6 weeks, bleeding would be induced with progestogen
treatment (as above). All participants were advised about timed intercourse
during the treatment cycles. Treatment continued until pregnancy or for up
to six ovulatory cycles. Participants who failed to ovulate on the maximum
dose (two tablets) or to conceive after six ovulatory cycles were crossed
over to the other drug (after a 6-week wash-out period) following the same
procedures as with the ﬁrst drug. The obstetric records of those conceiving
were reviewed for pregnancy outcomes.
During the course of treatment, if ovulation stopped after an initial posi-
tive response, the dose was increased in the subsequent cycle; if already
on the high dose, the participant was crossed over to the second drug; or
the study was ended if already on the second medicine. The maximum
number of cycles per treatment remained seven.
Outcomes
The primary outcome was clinical pregnancy (diagnosed by ultrasonographic
visualization of a gestational sac) rate per patient on primary treatment
(before the crossover). Secondary outcomes included ovulation, live-birth
(LB), pregnancy per ovulating patient, pregnancy per strata, mono-ovulation,
endometrial development (thickness and grades), pregnancy outcome and
pregnancy complications. Other outcomes included pregnancy and LB rates
on secondary and overall (primary and secondary) treatments.
Endometrial grades
Mid-cycle endometrial pattern was assessed and classiﬁed into three grades
A, B and C according to Zhao et al. (2014). Grade A endometrium has a
triple-line pattern, characterized by three hyperechogenic lines (a central
and two outer lines) separated by two hypoechogenic areas. Grade C endo-
metrium has a homogenous (non-triple line) hyperechogenic appearance.
Grade B endometrium has an intermediate pattern with a poorly deﬁned
central echogenic line surrounded by iso- or hypoechogenic layers.
Sample size
To detect a clinically signiﬁcant difference of 20% between the previously
reported pregnancy rate of CC (~35%) and letrozole with a two-sided 5% sig-
niﬁcance level and power of 80%, a sample size of 212 participants (106 per
arm) was required (Dickey and Holtkamp, 1996; Kousta et al., 1997; Imani
et al., 2002). In view of the lack of literature data on letrozole before this trial, it
was pre-planned in the protocol to perform an interim analysis during the trial
with a view to re-calculating the sample size based on the obtained data. An
interim blind analysis of the primary outcome after 50% recruitment (n = 106)
revealed pregnancy rates of 41.5 and 64.2% for drug A (CC) and B (letrozole),
respectively (P = 0.020, rate ratio [RR] 1.5 [1.1–2.3]; absolute difference [AD]
23% [4–40%]). Although, the difference was statistically signiﬁcant, the power
of the study was only 65%. Based on these data, the sample size was recalcu-
lated as 75 participants per arm to achieve 80% power with a two-sided 5% sig-
niﬁcance level. We aimed to recruit 160 participants to allow for 5% drop-outs.
Randomization
An independent pharmacist randomly allocated participants to letrozole or
CC, in 1:1 ratio according to a randomization list created by the trial statis-
tician using NQuery Advisor v6.0 software. Randomization was stratiﬁed
by patients’ BMI (non-obese <30 kg/m2 and obese 30–35 kg/m2) using
mixed block sizes. The randomization list included the patient study num-
ber and the treatment code (A or B). The participant study number was
indicated on the prescription and used by the pharmacist to determine the
allocated treatment. Investigators, patients, outcome assessors and the
statistician were blinded to the allocation of participants.
Blinding
Letrozole 2.5 mg Tablets (Femara® Novartis Pharmaceuticals UK Ltd) and
CC 50 mg Tablets (Clomid® Sanoﬁ UK) were encapsulated in identical
opaque capsules by ML(IMP)-licensed Pharmacy Production Units (initially
Royal Hallamshire Hospital, Shefﬁeld UK and later St Mary’s
Pharmaceutical Unit Cardiff and Vale University LHB, Cardiff, UK).
The capsules were packed in identical bottles of ﬁve capsules, which were
labelled in accordance with Annex 13 of the Rules and Guidance for
Pharmaceutical Manufacturers and Distributors. The packs were supplied to
the Pharmacy Department, Royal Derby Hospital with additional labels
allowing the Pharmacy Staff to identify the contents. At the time of dispens-
ing to the participant these identiﬁers were removed. While the Pharmacy
staff were aware of the patient’s allocated treatment throughout the study,
the patients and all investigators, including clinicians, research nurses, sono-
graphers and the statistician remained blinded to the treatment. The
Pharmacy Department had procedures in place to allow the treatment for
any participant to be unblinded at any time in case of emergency. Unblinding
was necessary in one case who developed a skin rash, suspected to be a
reaction to the trial drug, and she was withdrawn from the study (Fig. 1).
Further assessment of the rash excluded any reaction to the trial medicine.
Neither letrozole nor CC manufacturers were involved in the trial.
Participant compliance monitoring
Participants were asked to return all study packs (including empty bottles)
to Pharmacy. Details of returns were recorded on the dispensing log. All
participants who completed the study complied well to their prescriptions.
Statistical analysis
Statistical analysis was performed using PASW Statistics 18. Intention-to-
treat (ITT) analysis included all randomized subjects, regardless of whether
or not they received the study drug. Per protocol (PP) analysis included all
randomized subjects who received the study drug and were not lost to
follow-up. Participants who were lost to follow-up were assumed neither
to be pregnant nor to have given LB in the ITT analysis.
Three groups were analysed including primary, secondary and strategy
treatment groups. The ‘primary’ treatment group was deﬁned as the group
of participants who received the ﬁrst treatment before the crossover. The
‘secondary’ treatment group was deﬁned as the group of patients who
received the second treatment after the crossover. The ‘strategy’ treat-
ment group was deﬁned as the group of women who received the primary
treatment followed by the secondary one.
Per cycle analysis was conducted for the primary treatment including
pregnancy, LB, ovulation, mono-ovulation (cycles with one follicle ≥18)
and endometrial parameters (grades and thickness).
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Participants’ characteristics in the two allocated treatment sequences
were described without formal statistical testing at baseline. Categorical data
were compared using the chi-squared test. In addition, the RR and the AD
(95% CI) were estimated for pregnancy, ovulation and LB rates (Miettinen
and Nurminen, 1985; Newcombe, 1998). The length of time (measured as
number of treatment cycles) from randomization to pregnancy during the
‘primary’ treatment was compared using Kaplan Maier plot and the log rank
test. The endometrial thickness was compared using independent t-test.
Assessed for eligibility (n = 202)
Excluded (n = 43)
Not meeting inclusion criteria (n = 25)
Declined to participate (n = 8)
Conceived before consent (n = 10)
Allocated to CC (n = 79)
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Did not receive CC (n = 2)
(Conceived before treatment)
En
ro
llm
en
t
Allocated to Letrozole (n = 80)
Received Letrozole (n = 78)
Did not receive Letrozole (n = 2)
(Conceived before treatment)
• Discontinued intervention (n = 3)
- Failed to attend (n = 3)
• Conceived (n = 32)
• Discontinued intervention (n = 3)
- Social reasons (n = 1)
- Failed to attend (n = 1)
- Withdrew consent (n = 1)
• Conceived (n = 47)
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Analyzed ITT primary treatment
(n = 80)
Analyzed PP primary treatment
(n = 75)
Analyzed ITT primary treatment
(n = 79)
Analyzed PP primary treatment
(n = 74)
Randomised (n = 159)
• Lost to follow up (n = 3) 
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Figure 1 CONSORT diagram showing the ﬂow of participants through each stage of the crossover randomized trial. ITT, intention-to-treat; PP, per
protocol. *Three of the ﬁve participants failed to attend before the crossover. **Three of the four participants failed to attend before the crossover.
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Results
Participant ﬂow
Figure 1 shows the ﬂow of participants through the trial. A total of 202
eligible women were invited, of whom 159 were randomized. Four
women (two in each group) conceived before starting treatment and
six (three in each group) were lost to follow-up before completing the
ﬁrst treatment. The remaining 149 participants (CC, n = 74 on; letro-
zole, n = 75) completed at least the ﬁrst treatment as per protocol. In
total, 79 women conceived during the ﬁrst treatment and the remain-
ing 76 participants (letrozole, n = 31; CC, n = 45) were eligible to
crossover to the second treatment and were included in the ITT ana-
lysis for the secondary treatment.
Baseline data
Baseline demographic, clinical and endocrine characteristics of the two
trial groups were similar (Table I).
Primary outcome (pregnancy rates on
primary treatment)
ITT analysis revealed signiﬁcantly (P = 0.022) higher pregnancy rates
on letrozole compared to CC (Table II). The PP analysis revealed simi-
lar results (P = 0.018) as shown in Supplementary Table SI.
Secondary outcomes on primary treatment
Table II illustrates secondary outcomes including LB (overall and per
strata), ovulation, pregnancy per ovulating patient and pregnancy per
strata (ITT analysis). In addition, per cycle success rates including preg-
nancy, ovulation and LB are also shown. PP analysis results were simi-
lar as shown in Supplementary Table SI.
There was no statistically signiﬁcant difference in the LB rates
between the two drugs neither in the overall groups nor in different
BMI strata, although there was a trend towards higher rates in the
letrozole arm.
Pregnancy rate per ovulating woman was signiﬁcantly (P = 0.024)
higher with letrozole compared to CC. In strata one, women receiving
letrozole achieved 50% (P = 0.025) higher pregnancy rate than those
receiving CC. With regards to strata 2, there was no statistically signiﬁ-
cant difference in pregnancy rates between the two groups. Ovulation
rates per patient were not statistically different.
Sub-analysis of pregnancy rates based on different PCOS pheno-
types (e.g. presence of hyperandrogenaemia/ultrasound features)
revealed no statistically signiﬁcant difference between the two drugs
(Supplementary Table SII).
Per cycle analysis revealed signiﬁcantly higher pregnancy (P = 0.036)
and ovulation (P = 0.045) rates in the letrozole group, whilst LB rates
were not statistically (P = 0.087) different.
Outcomes on secondary and strategy
treatment
After the crossover, 45 women with CC-resistance/failure were allo-
cated to letrozole and 31 with letrozole-resistance/failure were allo-
cated to CC (Fig. 1). Pregnancy and LB rates were not signiﬁcantly
(ITT, P = 0.539 and P = 0.601, respectively) different between letro-
zole (28.9 and 24.4%, respectively) and CC (22.6 and 19.4%).
Pregnancy and LB rates achieved with letrozole followed by CC
(70.0 and 56.2%, respectively) were not statistically (ITT, P = 0.166
and P = 0.369, respectively) different from those (59.5 and 49.4%)
achieved with CC followed by letrozole.
Follicular and endometrial development
Mono-ovulation rates were similar between the two groups (Table II).
The median (IQR) mid-cycle endometrial thickness was signiﬁcantly
(P = 0.002) greater during CC treatment compared to letrozole.
Midcycle endometrial grades were not statistically (P = 0.141) different
between the two groups (Table II).
Dose and duration of treatment
Amongst the 49 letrozole pregnancies, 32 (65.3%) were achieved on
the low dose and 17 (34.7%) on the high dose. This was not signiﬁ-
cantly (P = 0.613) different from the dosages of 34 CC pregnancies
(low, 24 [70.6%] and high, 10 [29.4%]).
The median number of treatment cycles received until pregnancy
was signiﬁcantly (log rank P = 0.038) smaller with letrozole (4[3–5]
cycles) compared to CC (6[4–7] cycles).
........................................................................................
Table I Baseline characteristics of participants.
Letrozole (n= 80) CC (n = 79)
Age (years) 28.3 (4.4) 28.1 {(4.2)}
BMI (kg/m2) 27.5 (23.4 to 32.2) 27.7 (23.0 to 31.0)
Infertility duration (years) 1.5 (1.0 to 2.0) 1.5 (1.0 to 2.0)
LH (iu/l) 11.8 (8.9 to 15.2) 10.2 (6.2 to 13.3)
FSH (iu/l) 5.0 (1.6) 5.1 {(1.4)}
Testosterone (nmol/l) 1.8 (1.4 to 2.3) 1.9 (1.2 to 2.4)
FAI (%) 5.5 (3.0 to 7.8) 5.0 (3.0 to 8.0)
Prolactin (nmol/l) 219.5 (170 to 302.5) 214.0 (154 to 271)
Fasting insulin (mIU/L) 7.7 (4.2 to 11.6) 7.4 (4.5 to 20.4)
Fasting glucose (mM) 4.9 (4.6 to 5.1) 4.9 (4.6 to 5.3)
Rt Ovarian volume (ml) 11.5 (9.2 to 15.0) 12.0 (9.1 to 15.5)
Lt Ovarian volume (ml) 10.5 (7.0 to 13.3) 11.8 (8.3 to 13.6)
Menses
Oligomenorrhoea 51 (63.8%) 44 (55.7%)
Amenorrhoea 21 (26.2%) 19 (24.1%)
Irregular 7 (8.8% 11 (13.9%)
Regular 1 (1.2%) 5 (6.3%)
Hirsutism 33 (38.8%) 40 (50.6%)
Acne 30 (36.2%) 31 (39.2%)
Primary infertility 54 (67.5)% 58 (5873.4%)
Primiparity 63 (78.8%) 65 (82.3%)
Ethnicity
Caucasian 68 (85.0%) 62 (78.5%)
South Asian 11 (13.8%) 13 (16.5%)
Other 1 (1.2%) 4 (5.0%)
Numerical data presented as mean (SD) or median (25th to 75th percentile).
Categorical data presented as n (%).
CC, clomiphene citrate; FAI, free androgen index; Rt, right; Lt, left.
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Pregnancy outcome and complications on
primary treatment
Pregnancy outcome and complications on primary treatment are
detailed in Table III. There were no signiﬁcant differences in fetal,
maternal, or neonatal complication rates. No fetal anomaly was
detected on primary treatment, but only one minor fetal anomaly
(dilated left kidney) was reported in the 20-week anatomy scan in a
CC pregnancy as secondary treatment. Amongst the 49 letrozole
pregnancies, there were three (6.1%) sets of twins (one identical and
two non-identical), which were not signiﬁcantly different from that (0/
34, 0%) in the CC pregnancies. Another set of identical twins was
achieved with letrozole as a secondary treatment. Two of the four sets
of twins were delivered at 33 and 36 weeks due to intrauterine growth
restriction, but there were no neonatal problems.
The preterm rates were not different between the two drugs as pri-
mary treatments (Table III). Amongst the four preterm births in the
letrozole group, three were near term (33–36 weeks) with good neo-
natal outcome. The remaining one was severely premature (26 weeks)
and the neonate survived after 20 weeks in neonatal intensive care
unit (NICU). The two preterm births of the CC group were severely
premature (27 and 23 weeks gestation) and both survived after several
months in NICU.
Adverse events
Serious adverse events included two cases of haemorrhagic cysts (one
in each arm) and one acute cholecystitis (CC group), requiring hospi-
talization. Both haemorrhagic cysts resolved spontaneously. Twelve
participants on letrozole developed minor adverse events including
cyst formation (n = 3), diarrhoea, nausea and vomiting (n = 2), hot
hands, heavy leg, headache, neck pain, urinary tract infection and skin
spots. Eleven women on CC experienced minor adverse events
including cyst formation (n = 3), hot ﬂushes (n = 3), migraine, low
mood, elevated lever enzymes and skin rash.
Discussion
To the best of our knowledge, this is the ﬁrst sufﬁciently powered
double-blind RCT comparing letrozole versus CC in Europe. We have
found letrozole to generate a pregnancy rate of 61%, which is 40%
(RR, 1.4) higher than that (43%) of the standard ﬁrst line CC in
anovulatory women with PCOS. Furthermore, letrozole also resulted
in a 40% (RR, 1.4) increase in the LB rate compared to CC (49 versus
35%, respectively), although this did not reach statistical signiﬁcance as
the study was not powered to address this outcome (power 36%,
alpha level 0.05). We also found that letrozole has signiﬁcantly shor-
tened the time-to-pregnancy compared to CC (four versus six treat-
ment cycles, respectively). In addition, we have reported relatively low
pregnancy rates on both drugs as secondary treatments (after the
crossover). This ﬁnding suggests a cross-resistance between the two
drugs. The incidence of twins with letrozole (6%) was not different
from the previously published 5–10% incidence of CC twins (Scialli,
1986; Imani et al., 1999). There were no differences in the other preg-
nancy outcomes, but the trial was not powered to assess these para-
meters. These data should therefore be considered preliminary.
Our PCOS participants fulﬁlled the universally accepted Rotterdam
diagnostic criteria of PCOS and had a median BMI of ~27 kg/m2. We
believe that this cohort is a good representation of PCOS women
receiving fertility treatment in most fertility centres. Our results are
therefore globally generalizable for clinical practice.
.............................................................................................................................................................................................
Table II Outcomes for letrozole versus CC as a primary treatment—intention-to-treat analysis
Outcome Letrozole (N = 80) CC (N = 79) Rate ratio (95% CI) Absolute difference (95% CI) P
Pregnancy rate 49/80 (61.2%) 34/79 (43.0%) 1.4 (1.1, 2.0) 18% (3–33%) 0.022
Live birth rate 39/80 (48.8%) 28/79 (35.4%) 1.4 (0.95, 2.0) 13% (−2 to 28%) 0.089
Ovulation rate 67/80 (83.8%) 63/79 (79.7%) 1.1 (0.9, 1.2) 4% (−8 to 16%) 0.513
Pregnancies per ovulating patient 47/67 (70.1%) 32/63 (50.8%) 1.4 (1.04, 1.9) 20% (3–30%) 0.024
Pregnancies—strata 1 (BMI <30) 37/54 (68.5%) 25/53 (47.2%) 1.5 (1.04, 2.1) 21% (3–38%) 0.025
Pregnancies—strata 2 (BMI 30–35) 12/26 (46.2%) 9/26 (34.6%) 1.3 (0.7, 2.7) 12% (−14 to 35%) 0.397
Live births—strata 1 (BMI <30) 29/54 (53.7%) 20/53 (37.7%) 1.4 (0.9, 2.2) 15% (−3 to 30%) 0.122
Live births—strata 2 (BMI 30–35) 10/26 (38.5%) 8/26 (30.8%) 1.3 (0.6, 2.7) 8% (−20 to 30%) 0.771
Pregnancies per cycle 49/261 (19.0%) 34/278 (12%) 1.5 (1.03, 2.3) 7% (0.4–13%) 0.036
Live births per cycle 39/261 (15%) 28/278 (10%) 1.48 (0.95, 2.33) 5% (−0.7 to 11%) 0.087
Ovulation per cycle 196/261 (75%) 187/278 (67%) 1.1 (1.01, 1.2) 8% (1–15%) 0.045
Mono-ovulation* 80/94 (85.1%) 64/77 (83.1%) 0.88 (0.4, 1.7) −2% (−13 to 9%) 0.723
ET (mm) [median (IQR)] 8.4 (7.0, 10.2) 9.0 (8.0, 11.0) 0.002
EG
A 67 (46.5%) 50 (36.2%)
0.141B 50 (34.7%) 51 (37.0%)
C 27 (18.8%) 37 (26.8%)
CC, clomiphene citrate; IQR, interquartile; ET, midcycle endometrial thickness; EG, endometrial grade.
*Mono-ovulation rate per ovulatory cycles, proportion of cycles with one follicle ≥18 mm.
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Our data are consistent with the recent Cochrane systematic
review, which reported 44% higher pregnancy rates with the letrozole
compared to CC alone with no adjuvants (OR = 1.44, 95% CI:
1.20–1.73, n = 2286) (Franik et al., 2014). However, the quality of evi-
dence presented in that review was deemed poor by the review
authors as most of the trials were neither randomized nor double
blinded. The only well-designed trial by Legro et al. (2014) had a selec-
tion bias towards markedly obese PCOS women, with two-thirds
of their cohort having BMI >30 kg/m2 (one-third over 40 kg/m2).
This may explain their signiﬁcantly lower pregnancy and LB rates
compared to our trial. They, however, reported (graphically) cumula-
tive LB data in 250 non-obese women (BMI ≤30.3 kg/m2) showing
no signiﬁcant (P = 0.39) difference between the two drugs. Although
we have also found no statistically signiﬁcant difference in LB rates in
non-obese women, our results showed an obvious trend towards
markedly higher LB rates with letrozole (53%) compared to CC
(37%) (Table II). In contrast, the difference in Legro’s trial was only
small in favour of letrozole. It is worth mentioning, however, that
both Legro’s trial and ours are underpowered for this outcome in
non-obese PCOS women.
As far as time-to-pregnancy and multiple pregnancy data are con-
cerned, our ﬁndings seem to differ from those of Legro’s trial.
However, this could simply be due to lack of sufﬁcient statistical power
to assess these outcomes in either of our trials (Legro et al., 2014).
Our letrozole safety data are consistent with several previous studies
showing no increase in fetal/neonatal anomalies in letrozole pregnan-
cies (Tulandi et al., 2006; Legro et al., 2014).
With regards to endometrial parameters, mid-cycle endometrium
was slightly thicker with CC compared to letrozole. However, this dif-
ference is unlikely to affect the chances of pregnancy. Although endo-
metrial thickness and pattern have been widely utilized as markers of
endometrial receptivity, more recent research does not support their
usefulness (Zhao et al., 2014). Our endometrial data therefore neither
support nor exclude an endometrial factor for the differences in preg-
nancy rates between the two drugs.
A possible explanation of the higher success of letrozole is the great-
er ovulation rate per cycle in the letrozole group. Legro et al. (2014)
hypothesized that the higher pregnancy rate with letrozole could be
due to lower mid-luteal serum estradiol level and higher progesterone
levels (probably due to sustained aromatase inhibition into the luteal
phase) (Scialli, 1986; Dickey and Holtkamp, 1996; Imani et al., 1999;
Legro et al., 2007, 2014).
It may be argued that excluding women with BMI >35 kg/m2 could
limit the applicability of our results in obese women. However, the
majority of fertility centres worldwide, especially in Europe, tend to
exclude markedly obese women from fertility treatment due to the
well-known associated challenges and risks (Zachariah et al., 2006).
Another possible limitation of this RCT may be argued to be using
pregnancy rather than LB as the primary outcome. However, we
believe that pregnancy rate is clinically important and relevant and is
commonly used in practice. A further slight concern is the long dur-
ation of the trial spanning over a 7-year period with potential differ-
ences in responses between the early and late recruits. However, the
results of the interim analysis, which included the early recruits, are
consistent with the ﬁnal results.
In conclusion, this trial provides compelling evidence for the super-
iority of letrozole over clomiphene citrate as a primary OI agent in
PCOS women with a 40% increase in pregnancy rates and with a
shorter time-to-pregnancy. We, therefore, recommend that letrozole
should replace CC as the ﬁrst line OI agent in PCOS. Further research
is required to investigate possible mechanisms of the increased preg-
nancy rates with letrozole and of the cross-resistance between the
two drugs.
Supplementary data
Supplementary data are available at Human Reproduction online.
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Table III Pregnancy outcome and complications on
primary treatment
Letrozole n (%) CC n (%) P
Pregnancy outcome
Miscarriage 9 (18.4) 6 (17.6)
0.822
Ectopic 1 (2.0) 0 (0.0)
Preterm 4 (8.2) 2 (5.9)
Term 35 (71.4) 26 (76.5)
Twins 3* (6.1) 0 (0) 0.201
Fetal anomalies** 0 (0) 0 (0)
Fetal complications 3 (11.1) 3 (7.9) 0.521
IUGR 2 (7.4) 2 (5.3)
Macrosomia 1 (3.7) 0 (0)
Malpresentation 0 (0) 1 (2.6)
Maternal complications 2† (7.4) 7‡ (18.4) 0.205
IOL 9 (32.1) 13 (33.3) 0.199
CS 7 (24.1) 7 (17.9) 0.124
Delivery complications 0 (0) 1¶ (2.6) 0.591
Neonatal hypoglycaemia 1 (3.7) 2 (5.3) 0.663
IOL, induction of labour; CS, caesarean section; IUGR, intrauterine growth
restriction.
*One set was identical twins—there was an additional set of identical twins on
letrozole as a secondary treatment.
**No anomalies on primary treatment as reported by 20-week anatomy fetal scan.
There was one Minor anomaly (Dilated left kidney) on CC as a secondary treat-
ment with no neonatal problems.
†1 case of gestational diabetes; 1 case of impaired glucose tolerance.
‡1 case of gestational diabetes; 2 cases of pregnancy induced hypertension; 3 cases
of antepartum haemorrhage; 1 case of premature rupture of membranes.
¶Shoulder dystocia.
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Supplementary Table SI Outcomes for clomiphene citrate (CC) versus letrozole as a primary treatment—per-protocol
analysis.
Outcome Letrozole CC Rate ratio (95% CI) Absolute difference (95% CI) P
Pregnancy rate 47/75 (62.7%) 32/74 (43.2%) 1.4 (1.1, 2.0) 19% (3–34%) 0.018
Live birth rate 37/75 (49.3%) 26/74 (35.1%) 1.4 (0.96, 2.1) 14% (−2 to 29%) 0.079
Ovulation rate 66/75 (88.0%) 60/74 (81.1%) 1.1 (0.9, 1.3) 7% (−5 to 19%) 0.173
Pregnancies per ovulating patients 47/66 (71.2%) 32/60 (53.3%) 1.3 (1.01, 1.8) 18% (1–30%) 0.038
Pregnancies—strata 1 (BMI <30) 35/51 (68.6%) 23/49 (46.9%) 1.5 (1.04, 2.1) 22% (2–39%) 0.028
Pregnancies—strata 2 (BMI = 30–35) 12/24 (50.0%) 9/25 (36.0%) 1.4 (0.7, 2.7) 14% (−13 to 38%) 0.322
...........................................................................
.............................................................................................................................................................................................
Supplementary Table SII Pregnancy rates for letrozole versus clomiphene citrate (CC) in subgroups of polycystic
ovarian syndrome (PCOS) women based on clinical and/or biochemical hyperandrogenaemia (HA) and PCOS phenotype.
PCOS subgroup Pregnancy rates P
Letrozole (N = 80) CC (N = 79)
Women with HA 43/70 (61.4%) 28/62 (45.2%) 0.080
Women without HA 6/10 (60.0%) 6/17 (35.3%) 0.257
Women with Full PCOS criteria* 39/64 (60.9%) 26/55 (47.3%) 0.145
Women with Two PCOS criteria** 10/16 (62.5%) 8/24 (33.3%) 0.106
*Full PCOS criteria: oligo-/anovulation + hyperandrogenaemia + polycystic ovaries.
**Two PCOS criteria: oligo-/anovulation + hyperandrogenaemia or polycystic ovaries.
